SCM
EDSA icon

Stonepine Capital Management’s Edesa Biotech EDSA Stock Holding History

Stonepine Capital Management’s Portfolio EDSA Stock Details EDSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$157K Sell
30,000
-657,500
-96% -$1.97M 0.06% 74
2025
Q4 		$976K Hold
687,500
– – 0.71% 39
2025
Q3 		$1.7M Buy
+687,500
New +$1.59M 1.38% 18
2025
Q2 		– Sell
-687,500
Closed -$1.68M – 67
2025
Q1 		$1.68M Buy
+687,500
New +$1.48M 1.63% 20

Other funds holding EDSA

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
SRL
Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

Stonepine Capital Management's EDSA Position: Q1 2026 in Review

Stonepine Capital Management reduced its Edesa Biotech (EDSA) stake by 96% in Q1 2026, selling an estimated $1.97M and leaving 30,000 shares worth $157K. The position accounts for 0.06% of the portfolio, ranked #74.

Stonepine Capital Management first reported a position in EDSA in Q1 2025 and has held it in 4 quarters since. The position peaked at $1.7M in Q3 2025. 28 funds tracked by Wall St. Rank hold EDSA as of Q1 2026.

  • Stonepine Capital Management held 30,000 shares of Edesa Biotech worth $157K as of Q1 2026.
  • Stonepine Capital Management sold 657,500 Edesa Biotech shares in Q1 2026, an estimated $1.97M.
  • Edesa Biotech made up 0.06% of Stonepine Capital Management's portfolio in Q1 2026, its #74 holding.
  • Stonepine Capital Management first reported a position in Edesa Biotech in Q1 2025 and has held it in 4 quarters since.
  • Stonepine Capital Management's Edesa Biotech position peaked at $1.7M in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Edesa Biotech as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.